Alphamab Oncology — Board/Management Information 2020

Dec 7, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [172 x 40] intentionally omitted <==

ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND

TERMINATION OF THE ENGAGEMENT OF THE CHIEF FINANCIAL OFFICER AND THE BOARD SECRETARY

The board (the “ Board ”) of directors (the “ Directors ”) of Alphamab Oncology hereby announces that the engagement of Mr. SHUAI Qi Terry (帥琪) (“ Mr. Shuai ”) as the chief financial officer, the board secretary, a joint company secretary and an authorized representative of the Company was terminated with effect from December 7, 2020.

The termination of Mr. Shuai’s engagement is primarily due to the unresolved disputes between Mr. Shuai and the Company regarding performance objectives and certain employment terms and therefore the Company believes that it’s not appropriate for Mr. Shuai to continue serving as the chief financial officer, the board secretary, a joint company secretary and an authorized representative of the Company going forward. The Company confirms that there are no other material matters with respect to the departure of Mr. Shuai to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”). The Board confirms that accounting, internal control, investor relations related matters of the Group are all in an orderly manner and the departure of Mr. Shuai will not have any material adverse effect on the operations of the Group.

The Board announces that Ms. WANG Jin’nan (王晉南) (“ Ms. Wang ”), the Company’s director of investor relations, has been appointed as a joint company secretary and an authorized representative of the Company with effect from December 7, 2020 (the “ Appointment Date ”). The biographical details of Ms. Wang are as follows:

Ms. WANG Jin’nan (王晉南), aged 38, a Chartered Financial Analyst (CFA). She has over ten years of experience in financing, investment and investor relationship management. Ms. Wang graduated from the Jilin University with a master’s degree in Economics. Prior to joining the Company, she has been a manager of Duff & Phelps, primarily responsible for providing fairness opinion on equity transactions, financing, mergers and acquisitions and investment. She has also served as investor relationship director and manager of two companies listed on the Stock Exchange.

1

The Board would like to welcome Ms. Wang on her new appointment.

Pursuant to Rules 3.28 and 8.17 of the Listing Rules, the Company must appoint a company secretary who, by virtue of his/her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of company secretary. Ms. Wang currently does not possess the relevant qualification as required under the Rules 3.28 and 8.17 of the Listing Rules. The Company has made application to the Stock Exchange for a waiver from the strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules (the “ Waiver ”). The appointment of Ms. Wang is subject to the Waiver to be granted by the Stock Exchange and the Company will make further announcements in due course.

By Order of the Board Alphamab Oncology Dr. XU Ting Chairman and Executive Director

Hong Kong, December 7, 2020

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.

2